MarketCap
Vertex Pharmaceuticals Incorporated VRTX
$ 505.75
0.2%
Facebook
X
Telegram
Vertex Pharmaceuticals Incorporated Financial Ratios 2025-2007 | VRTX
Brief overview of Vertex Pharmaceuticals Incorporated's valuation multiples
This overview follows the five latest available observations from 2020 through 2025.
The current valuation set is P/E 31.69x (median 24.16x), EV/EBITDA 18.22x (median 42.8x), P/S 10.44x (median 10.44x). On average, multiples differ from their five-year medians by only +7.5%. Valuation is near its familiar historical range.
Earnings yield calculated as 1/P/E is about 3.2%, showing current profit per unit of share price.
Returns on assets and capital are represented by ROE 21.2%, ROA 15.4%, ROCE 22.4%. Business quality is high on return ratios, supporting the ability to create value.
PEG of 0.63x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
The cash cycle lengthened by 172.7 days to 278.7 days. Operations require more funding.
Valuation takeaway
Vertex Pharmaceuticals Incorporated's profile looks neutral, with price and fundamental efficiency broadly aligned.
Annual Financial Ratios Vertex Pharmaceuticals Incorporated
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
31.7 | -223.1 | 30.3 | 22.9 | 24.2 | 22.6 | 50.2 | 22.7 | 157.3 | -184.3 | -39.4 | -35.1 | -41.5 | -88.4 | 240.7 | -9.1 | -8.1 | -8.7 | - |
P/S |
10.4 | 10.8 | 11.1 | 8.5 | 7.5 | 9.9 | 14.2 | 15.6 | 16.7 | 12.1 | 21.2 | 44.7 | 15.2 | 6.2 | 5.0 | 47.8 | 51.1 | 22.9 | - |
EPS |
15.5 | -2.1 | 14.1 | 13.0 | 9.1 | 10.4 | 4.6 | 8.2 | 1.1 | -0.5 | -2.3 | -3.1 | -2.0 | -0.5 | 0.1 | -3.8 | -3.7 | -3.3 | - |
EV (Enterprise Value) |
127 B | 121 B | 105 B | 69.8 B | 53.1 B | 58.5 B | 58.3 B | 46.7 B | 41.3 B | 21 B | 22.6 B | 26.5 B | 18.9 B | 10.5 B | 7.88 B | 7.83 B | 5.62 B | 3.62 B | -356 M |
EBITDA per Share |
17.1 | -0.1 | 15.6 | 17.4 | 11.3 | 11.4 | 5.1 | 2.9 | 1.83 | 0.297 | -1.67 | -2.46 | -0.672 | 0.2 | 1.25 | -3.32 | -3.37 | -3.06 | - |
EV/EBITDA |
29.0 | -4711.0 | 26.1 | 15.7 | 18.2 | 18.1 | 42.8 | 61.0 | 87.6 | 276.3 | -53.4 | -44.2 | -118.5 | 221.3 | 27.4 | -11.8 | -9.6 | -8.4 | - |
PEG |
-0.01 | -16.94 | 0.63 | 0.37 | 0.16 | 0.17 | -1.13 | 0.03 | 0.48 | -2.3 | -1.49 | 0.6 | 0.14 | 0.2 | 2.32 | - | - | - | - |
P/B |
6.7 | 7.3 | 6.2 | 5.5 | 5.6 | 7.1 | 9.7 | 10.7 | 20.3 | 15.4 | 20.0 | 23.6 | 13.6 | 7.9 | 7.4 | 13.6 | 4.7 | - | - |
P/CF |
34.5 | -242.6 | 31.0 | 18.4 | 21.4 | 18.9 | 39.6 | 40.5 | 70.8 | 115.0 | -53.3 | -45.9 | -179.4 | 48.1 | 144.8 | -10.8 | -12.2 | -17.7 | - |
ROE % |
21.18 | -3.26 | 20.59 | 23.88 | 23.19 | 31.22 | 19.34 | 47.28 | 12.90 | -8.37 | -50.87 | -67.38 | -32.81 | -8.95 | 3.06 | -149.74 | -58.57 | -192.51 | - |
ROA % |
15.42 | -2.38 | 15.92 | 18.30 | 17.44 | 23.07 | 14.15 | 33.57 | 7.43 | -3.87 | -22.26 | -31.63 | -19.19 | -3.88 | 1.34 | -43.74 | -32.84 | - | - |
ROCE % |
22.36 | -1.42 | 21.80 | 30.96 | 27.55 | 32.88 | 17.21 | 12.95 | 14.34 | 0.53 | -23.32 | -32.62 | -10.38 | 0.18 | 12.24 | -138.12 | -56.01 | -193.70 | - |
Current Ratio |
3.7 | 3.7 | 4.4 | 4.3 | 4.0 | 3.8 | 3.6 | 3.4 | 3.3 | 2.3 | 2.8 | 4.2 | 4.0 | 3.7 | 3.4 | 1.4 | 2.3 | - | - |
DSO |
55.7 | 52.5 | 55.6 | 52.7 | 48.7 | 44.7 | 55.5 | 57.1 | 56.4 | 43.8 | 66.9 | 56.6 | 25.8 | 34.2 | 47.4 | 28.2 | 17.2 | - | - |
DIO |
319.6 | 231.8 | 173.4 | 137.5 | 127.9 | 111.1 | 111.6 | 110.8 | 148.4 | 134.6 | 167.7 | 184.6 | 39.6 | 39.7 | 509.7 | - | - | - | - |
DPO |
96.7 | 92.8 | 96.7 | 84.3 | 70.7 | 60.2 | 58.4 | 98.9 | 98.2 | 106.6 | 219.7 | 426.1 | 138.2 | 132.1 | 338.4 | - | - | - | - |
Operating Cycle |
375.3 | 284.4 | 229.0 | 190.2 | 176.7 | 155.8 | 167.2 | 167.9 | 204.8 | 178.4 | 234.6 | 241.3 | 65.4 | 74.0 | 557.1 | 28.2 | 17.2 | - | - |
Cash Conversion Cycle |
278.7 | 191.6 | 132.3 | 105.9 | 106.0 | 95.6 | 108.8 | 69.0 | 106.6 | 71.8 | 14.9 | -184.8 | -72.8 | -58.1 | 218.7 | 28.2 | 17.2 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Vertex Pharmaceuticals Incorporated
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
4.34 | 4.06 | - | 4.24 | 4.02 | 2.52 | - | 4.05 | -13.92 | 4.26 | - | 4.01 | 3.55 | 2.72 | - | 3.63 | 3.17 | 2.99 | - | 3.3 | 0.26 | 2.52 | 2.32 | 2.56 | 3.22 | 2.32 | 2.26 | 0.22 | 1.04 | 1.05 | 6.08 | 0.51 | 0.82 | 0.83 | 0.4 | -0.41 | 0.07 | 1.01 | 0.13 | -0.16 | -0.26 | -0.17 | -0.3 | -0.39 | -0.78 | -0.83 | -0.74 | -0.72 | -0.68 | -1 | 0.19 | -0.54 | -0.26 | -1.43 | -0.35 | -0.27 | -0.31 | 0.44 | 0.76 | 1.06 | -0.85 | -0.87 | -1.04 | -1 | -0.83 |
EBITDA per Share |
5.14 | 4.7 | - | 4.85 | 4.69 | 2.64 | - | 4.53 | -13.4 | 4.62 | - | - | - | 3.18 | - | 4.82 | 4.32 | 4.22 | - | 4.44 | -0.15 | 3.53 | 2.87 | 2.89 | 2.97 | 2.88 | 2.14 | 0.7 | 1.27 | 1.19 | 0.5 | 1.02 | 0.82 | 0.57 | 0.5 | -1.12 | 0.33 | 1.16 | 0.16 | 0.11 | 0.14 | 0.01 | -0.22 | -0.1 | -0.58 | -0.65 | -0.64 | -0.4 | -0.64 | -0.86 | -0.04 | -0.4 | -0.12 | -1.94 | -0.36 | 0.12 | 0.03 | 0.48 | 1.08 | 1.17 | -0.73 | -0.75 | -0.88 | -0.77 | -0.77 |
ROE % |
23.03 | 21.51 | 16.18 | 22.87 | -7.70 | -7.79 | -11.71 | -5.44 | -6.21 | 22.97 | 17.04 | 24.18 | 24.70 | 25.77 | 20.92 | 29.86 | 23.45 | 23.93 | 16.94 | 23.89 | 22.64 | 31.55 | 31.22 | 33.84 | 27.11 | 22.74 | 20.22 | 45.59 | 49.08 | 51.52 | 55.87 | 25.87 | 16.36 | 9.53 | 12.99 | 10.87 | 12.59 | 6.12 | -9.69 | -20.38 | -27.15 | -41.66 | -59.19 | -67.78 | -73.47 | -68.21 | -68.70 | -49.00 | -42.34 | -31.72 | -32.81 | -43.70 | -40.30 | -42.59 | -10.71 | 17.07 | 50.93 | 35.31 | 3.76 | -48.54 | -100.83 | -95.39 | -32.14 | -24.18 | -16.68 |
ROA % |
16.56 | 15.37 | 11.48 | 16.18 | -6.03 | -5.73 | -8.55 | -3.79 | -3.99 | 17.55 | 12.95 | 18.52 | 19.10 | 21.35 | 17.67 | 18.21 | 12.64 | 18.04 | 12.69 | 17.83 | 16.76 | 23.34 | 23.07 | 24.94 | 19.96 | 16.05 | 14.15 | 31.96 | 33.33 | 33.44 | 33.57 | 11.59 | 6.62 | 3.81 | 7.43 | 5.73 | 7.29 | 4.56 | -3.87 | -7.96 | -10.42 | -15.75 | -22.27 | -26.88 | -30.36 | -29.63 | -31.63 | -22.16 | -20.23 | -15.86 | -19.19 | -23.86 | -20.59 | -20.48 | -3.88 | 6.08 | 18.19 | 12.65 | 1.34 | -16.92 | -39.04 | -40.48 | -11.06 | -12.09 | -9.34 |
ROCE % |
25.59 | 23.25 | 17.37 | 24.51 | -6.13 | -6.68 | -10.50 | -4.22 | -4.72 | 24.46 | 18.32 | 26.97 | 29.95 | 32.86 | 27.46 | 38.53 | 29.47 | 30.08 | 20.54 | 29.12 | 25.80 | 34.48 | 32.88 | 33.36 | 27.25 | 24.31 | 20.57 | 14.39 | 19.83 | 20.94 | 21.76 | 25.08 | 1.93 | -1.91 | 6.08 | 3.30 | 17.76 | 15.45 | 0.86 | -8.28 | -14.11 | -32.61 | -49.67 | -58.25 | -64.03 | -62.61 | -64.41 | -50.88 | -46.76 | -33.43 | -44.97 | -51.97 | -42.97 | -40.58 | 0.23 | 36.44 | 63.96 | 43.96 | 14.47 | -44.69 | -92.61 | -87.70 | -30.70 | -20.50 | -16.18 |
Current Ratio |
3.8 | 3.7 | 3.7 | 3.3 | 3.5 | 3.6 | 3.7 | 3.4 | 3.8 | 4.5 | 4.4 | 4.2 | 4.2 | 4.2 | 4.3 | 4.5 | - | 4.3 | 4.0 | 4.1 | 4.0 | 3.9 | 3.8 | 3.8 | 3.8 | 3.8 | 3.7 | 3.7 | 3.7 | 3.7 | 3.5 | 3.5 | 3.5 | 3.5 | 2.4 | 2.4 | 2.4 | 2.4 | 1.9 | 1.9 | 1.9 | 1.9 | 1.8 | 1.8 | 1.8 | 1.8 | 1.9 | 1.9 | 1.9 | 1.9 | 2.4 | 2.4 | 2.4 | 2.4 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.8 | 1.5 | 2.0 | 2.3 |
DSO |
56.5 | 61.9 | - | 57.0 | 56.9 | 56.2 | - | 56.1 | 59.5 | 56.9 | - | 56.9 | 56.8 | 57.4 | - | 27.1 | 26.9 | 52.9 | - | 46.7 | 48.5 | 49.3 | 49.6 | 52.5 | 53.0 | 45.7 | 40.9 | 60.9 | 61.4 | 55.5 | 43.0 | 47.6 | 49.7 | 49.2 | 39.4 | 44.4 | 47.2 | 30.8 | 39.9 | 44.3 | 42.5 | 43.0 | 38.0 | 51.8 | 97.6 | 83.5 | 48.0 | 38.7 | 50.1 | 62.2 | 22.2 | 35.2 | 25.1 | 31.8 | 39.1 | 38.9 | 31.2 | 33.9 | 29.7 | 25.4 | 146.1 | 116.5 | 16.3 | 16.5 | - |
DIO |
329.4 | 401.1 | - | 343.9 | 320.1 | 322.4 | - | 231.8 | 212.0 | 206.7 | - | 185.0 | 168.3 | 170.2 | - | 61.2 | 59.1 | 128.4 | - | 126.4 | 124.2 | 137.5 | 126.2 | 137.6 | 138.8 | 125.9 | 82.6 | 115.9 | 112.6 | 140.0 | 92.8 | 102.0 | 108.7 | 150.5 | 121.4 | 140.0 | 143.3 | 183.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
85.7 | 110.5 | - | 94.9 | 99.3 | 107.8 | - | 84.1 | 83.3 | 95.4 | - | 105.8 | 101.5 | 107.2 | - | 20.0 | 30.2 | 68.4 | - | 49.3 | 51.1 | 67.1 | 69.7 | 76.0 | 76.7 | 68.2 | 43.2 | 60.6 | 58.9 | 95.3 | 82.8 | 91.0 | 97.0 | 117.8 | 80.3 | 92.7 | 94.8 | 131.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | 463.0 | - | 400.8 | 377.0 | 378.6 | - | 287.8 | 271.4 | 263.6 | - | 241.8 | 225.1 | 227.7 | - | 88.3 | 85.9 | 181.3 | - | 173.1 | 172.7 | 186.8 | 175.8 | 190.1 | 191.8 | 171.6 | 123.5 | 176.7 | 174.0 | 195.5 | 135.8 | 149.7 | 158.4 | 199.7 | 160.8 | 184.4 | 190.5 | 214.7 | 39.9 | 44.3 | 42.5 | 43.0 | 38.0 | 51.8 | 97.6 | 83.5 | 48.0 | 38.7 | 50.1 | 62.2 | 22.2 | 35.2 | 25.1 | 31.8 | 39.1 | 38.9 | 31.2 | 33.9 | 29.7 | 25.4 | 146.1 | - | - | - | - |
Cash Conversion Cycle |
- | 352.5 | - | 305.9 | 277.7 | 270.8 | - | 203.7 | 188.1 | 168.2 | - | 136.1 | 123.7 | 120.5 | - | 68.3 | 55.7 | 112.9 | - | 123.8 | 121.6 | 119.7 | 106.1 | 114.1 | 115.1 | 103.5 | 80.3 | 116.1 | 115.1 | 100.2 | 52.9 | 58.6 | 61.4 | 81.8 | 80.5 | 91.8 | 95.7 | 83.2 | 39.9 | 44.3 | 42.5 | 43.0 | 38.0 | 51.8 | 97.6 | 83.5 | 48.0 | 38.7 | 50.1 | 62.2 | 22.2 | 35.2 | 25.1 | 31.8 | 39.1 | 38.9 | 31.2 | 33.9 | 29.7 | 25.4 | 146.1 | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Vertex Pharmaceuticals Incorporated, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Britain
France
Israel
Germany
Russia
Belgium
Cayman-islands
